In May of 2014 Aldeyra Therapeutics (ALDX), a late stage clinical development biotechnology company developing and commercializing next generation medicines for patients with immune mediated, ocular and systemic diseases completed a $12,000,000, retail centric IPO. Since then, the company has raised over $125,000,000. Following the company’s IPO, Laidlaw’s capital markets team was introduced to (ALDX) and consummated a robust healthcare centric institutional roadshow effort. After 50+ introductions to potential investors, in January 2015 Laidlaw was exclusive placement agent on their first financing since their IPO – a $8mm PIPE transaction, where we successfully helped institutionalize the company with some marquee shareholders, many that are still partners to the company today. Laidlaw Capital Markets team has stayed committed to continuing to working with the team at ALDX to make relevant introductions, build awareness in the name and be a supportive sponsor to the company. Please find a timeline of the relationship below.